Invested in
BioMarin Pharmaceutical?
Contact investor lawyers for a free evaluation of your potential claims for compensation today.
- Are you an investor in BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and have you held your BMRN shares since January 2020 or earlier?
- Are you concerned about the recently reported allegations of misleading statements and failure to disclose in connection to BioMarin’s product candidate BMN 307?
- Would you like your potential options for compensation and/or redress to be reviewed by an experienced team of investor lawyers?
Request a free case evaluation via email at arosca@rscounsel.law, leave a message through the contact form on this page, or call us at 888-998-0530.
Contact Us About Your
Investments
Free Case Evaluation
The Biomarin Pharmaceutical Investor Center is the Resource for Investors Who Invested in Biomarin Pharmaceutical Shares.
- Free Case Evaluation
- No Fees if No Recovery
- Contact Us Today
We can also do a Zoom call to discuss your matter.
Posted July 22, 2022
BioMarin Pharmaceutical Investigation
Securities attorneys Alan Rosca and Paul Scarlato have been investigating alleged securities violations, corporate misconduct, and questionable business practices and misrepresentations involving BioMarin and have identified potential areas of concern.
BMRN stock investors interested to evaluate potential options to seek compensation and/or pursue claims related to their BioMarin Pharmaceutical holdings may contact investor rights attorneys Alan Rosca and Paul Scarlato. Attorneys Rosca and Scarlato have extensive experience in seeking compensation related to investor harm and pursuing claims arising out of corporate misconduct and are currently evaluating potential claims on behalf of investors in BioMarin They typically work on a contingent fee basis, do not require any money down from their clients, advance case expenses, and only get paid for their fees and expenses if and when successful, pursuant to court review and approval.
Claims that are not timely pursued may expire or otherwise be lost, generally speaking. BioMarin Pharmaceutical investors interested to explore options to file claims should consider taking action promptly.
Concerned BMRN stock investors may contact attorneys Alan Rosca or Paul Scarlato to discuss their potential options toll free at 888-998-0530, via email at arosca@rscounsel.law, or through the contact form on this webpage.
About BioMarin Pharmaceutical Inc.
BioMarin Pharmaceutical Inc. is a biotechnology company incorporated in Delaware and with offices in San Rafael, California. BioMarin reportedly develops and commercializes innovative therapies for people with serious and life-threatening rare diseases and medical conditions. The company’s common stock is listed under the symbol “BMRN” on the Nasdaq Global Select Market.
BioMarin’s portfolio consists of several commercial therapies and multiple clinical and preclinical product candidates. One of the company’s major product candidates is BMN 307, an AAV5 mediated gene therapy product reportedly developed for the treatment of phenylketonuria (“PKU”). The FDA reportedly granted IND status for BMN 307 for the treatment of PKU in January 2020, and the dosing of first human participant in the study of BMN 307 called Phearless Phase ½ was announced in September 2020.
BioMarin Pharmaceutical Announces Clinical Hold on BMN 307
On September 5, 2021, BioMarin issued a press release announcing that “the U.S Food and Drug Administration (FDA) placed a clinical hold on the BMN 307 Phearless Phase 1/2 study.” The company further indicated that “the clinical hold was based on interim safety findings from a pre-clinical, non-GLP pharmacology study.”
On this news, BioMarin’s stock price fell $7.14 per share, or 8.4%, to close at $77.81 per share on September 7, 2021, the next trading day.
BioMarin Pharmaceutical Class Action Complaint Alleges Securities Violations
On October 22, 2021, a class action complaint was filed against BioMarin Pharmaceutical Inc., Jean-Jacques Bienaimé (BioMarin’s CEO), Brian R. Mueller (CFO), Daniel Spiegelman (EVP and CFO), and Henry J. Fuchs (President of Worldwide Research & Development).
The plaintiffs allege, among others, that the Defendants made materially false or misleading statements in connection with BMN 307 safety, and the clinical and commercial prospects of the BMN 307 product. As a result, the plaintiffs are seeking damages, as well as their reasonable attorneys’ fees, expert fees and other costs.
Potential Compensation Claims
BioMarin Pharmaceutical Shareholders May Have Options
Investor rights attorneys Alan Rosca and Paul Scarlato at Rosca Scarlato LLC are investigating potential options and are evaluating potential claims on behalf of BMRN shareholders. They have decades of combined experience representing victims of corporate or financial misconduct.
If you are a BioMarin Pharmaceutical investor concerned about your investment, you may contact attorneys Alan Rosca or Paul Scarlato to learn more about your rights and for an evaluation of your case, or to provide useful information. All consultations are free. The Rosca Scarlato LLC attorneys typically take cases like this on a contingency fee basis, advance all case costs, and only get paid for their fees and expenses if and when they are successful, following review and approval by the Court of any fee application.
To reach attorney Alan Rosca or his colleagues, BioMarin Pharmaceutical investors may call 888-998-0530, email arosca@rscounsel.law, or leave a message through the contact form on this webpage.
These general considerations are for informational purposes only and do not constitute legal advice. Such legal advice can only be offered once the attorneys discuss each investor’s situation, learn of the relevant facts and can tailor any advice to that investor’s facts. BioMarin Pharmaceutical investor center is not affiliated with BioMarin Pharmaceutical Inc.
Contact info:
Rosca Scarlato LLC – 216-946-7070 / 888-998-0530.
Alan Rosca – arosca@rscounsel.law
Paul Scarlato – pscarlato@rscounsel.law
Recent Investigations
- Posted on
- Posted on
DISCLAIMER
In our legal system, every person is innocent until and unless found guilty by a court of law or a tribunal. Whenever we reference “allegations” or charges that are “alleged,” such allegations or charges have not been proven, and are merely accusations, not findings of fault, as of the date of the blog. We do not have, nor do we undertake, a duty to continue to monitor or follow matters about which we report, and/or to publish subsequent updates regarding various developments that may occur in such matters. Readers are encouraged to conduct their own research regarding any such matters and any developments that may or may not have occurred in such matters. Also, the Brokercheck report linked to some of our blogs is the up-to-date version as of the date of accessing by the reader. The information in our blogs is current as of the date of the drafting of the blog, and given that sometimes certain past complaints may no longer be listed in newer Brokercheck reports, some of the events referenced in some of our blogs may later on be removed from newer Brokercheck reports. Visitors may check the most recent version of each brokercheck report at www.finra.org, and may contact FINRA for the earlier version of the Brokercheck report upon which various blogs may be based.